Assertio announced that it is providing educational grant funding for the Lennox-Gastaut Syndrome, LGS, Foundation’s new About LGS Treatments Kits for families coping with LGS. Assertio markets SYMPAZAN oral film CIV, approved by the U.S. Food and Drug Administration, FDA, for the adjunctive treatment of seizures associated with LGS in patients aged two years of age or older. Assertio announced in December that it provided a $100,000 educational grant to the LGS Foundation. "Assertio is proud to support the LGS community," said Dan Peisert, President and Chief Executive Officer of Assertio. "Our focus is on working with the LGS Foundation to help raise awareness of LGS and to support development of educational materials that can benefit their community."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ASRT:
- Spectrum Pharma Skyrockets on Acquisition by Assertio
- Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction
- Assertio Provides Educational Grant for New Lennox-Gastaut Syndrome (LGS) Foundation Treatments Kits
- Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Assertio Holdings sees FY23 product sales $150M-$160M, consensus $154.61M